EUVIMEDEUVIMED entdecken
Validierungsstudie

Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs

Xuelei Zhu iD, Yan Luo, Yi Zhang, Huamei Zhou, Jiao Xiang, Yunhua Su, Lijing Chen

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.70063 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Xuelei Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The People's Hospital of Nanchuan, Chongqing, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Thyroid Cancer, Papillary, Thyroid Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This research seeks to identify and verify the prognostic signature of immune‐related RNA of papillary thyroid carcinoma (PTC). The Cancer Genome Atlas (TCGA) database provided the PTC samples and clinical data. Using the limma program, differentially expressed mRNAs and lncRNAs (DElncRNAs) were found. A risk score (RS) model was created by using univariate and multivariate Cox regression analyses to find lncRNAs associated with overall survival prognosis. The association between the lncRNA prognostic signature and the invasion of several immune cell subtypes was investigated using the Tumor Immune Estimation Resource (TIMER). To verify the expression of the prognostic signature, RT‐PCR was utilized. From TCGA, 491 PTC tumor samples were acquired, comprising 18497 mRNAs and 2525 lncRNAs. There were 138 DElncRNAs and 494 differentially expressed mRNAs. Six DElncRNAs with independent prognoses were then selected from a total of 138 DElncRNAs. According to the TIMER database, the 6‐DElncRNA PTC prognostic signature was correlated with the invasion of several immune cell subtypes. The expression patterns of four DElncRNAs matched the database results, according to RT‐PCR analysis. Six lncRNAs were found to constitute a predictive characteristic for PTC in this study, and these signatures were connected to the infiltration of different immune cell subtypes. These findings provide a potential basis for the development of diagnostic biomarkers and immunotherapeutic stratification in PTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorHumansPrognosisMaleFemale

Stichwörter der Autor:innen

immune cell infiltration | immune‐related subtypes | papillary thyroid carcinom…

Substanzen

RNA, Long NoncodingBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Endocrinology, The People's Hospital of Nanchuan, Chongqing, China.

ORCID-Profile: Xuelei Zhu

Zitieren

APA

Zhu, X., Luo, Y., Zhang, Y., Zhou, H., Xiang, J., Su, Y., & Chen, L. (2025). Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.70063

Vancouver

Zhu X, Luo Y, Zhang Y, Zhou H, Xiang J, Su Y, et al. Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.70063

BibTeX
@article{Zhu2025,
  author = {Zhu, Xuelei and Luo, Yan and Zhang, Yi and Zhou, Huamei and Xiang, Jiao and Su, Yunhua and Chen, Lijing},
  title = {Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.70063}
}
Kostenlos starten →